Soluble urokinase plasminogen activation receptor-An emerging new biomarker of cardiovascular disease and critical illness

Nicole Cyrille, Pedro Villablanca, Harish Ramakrishna

Research output: Contribution to journalArticle

7 Scopus citations


Soluble urokinase plasminogen activation receptor (suPAR) is an emerging new biomarker, which has been shown to not only correlate with traditional biomarkers but also outperform CRP at prognosticating CVD. More clinical trials on suPAR is in the future research agenda.

Original languageEnglish (US)
Pages (from-to)214-216
Number of pages3
JournalAnnals of Cardiac Anaesthesia
Issue number2
StatePublished - Apr 1 2016



  • Biomarkers
  • Cardiovascular disease
  • Critical illness
  • Heart failure

ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine
  • Cardiology and Cardiovascular Medicine

Cite this